Mon, September 24, 2012
Sun, September 23, 2012
Fri, September 21, 2012
Thu, September 20, 2012
Wed, September 19, 2012
Tue, September 18, 2012
Mon, September 17, 2012
Sun, September 16, 2012
Fri, September 14, 2012
Thu, September 13, 2012
Wed, September 12, 2012
Tue, September 11, 2012
Mon, September 10, 2012
Sun, September 9, 2012
Fri, September 7, 2012
Thu, September 6, 2012
Wed, September 5, 2012

HeartWare Presentation at the UBS Global Life Sciences Conference to be Webcast


//health-fitness.news-articles.net/content/2012/ .. obal-life-sciences-conference-to-be-webcast.html
Published in Health and Fitness on Friday, September 14th 2012 at 6:34 GMT by Market Wire   Print publication without navigation


HeartWare Presentation at the UBS Global Life Sciences Conference to... -- FRAMINGHAM, Mass. and SYDNEY, Sept. 14, 2012 /PRNewswire/ --

HeartWare Presentation at the UBS Global Life Sciences Conference to be Webcast

[ ]

FRAMINGHAM, Mass. and SYDNEY, Sept. 14, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: [ HTWR ] - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the UBS Global Life Sciences Conference at 8:00 a.m. EDT on Wednesday, September 19, 2012.  The conference is being held September 19-20, 2012 at the Grand Hyatt in New York City.

A live webcast of the Company's presentation at the conference will be available via a link provided at [ www.heartware.com ].  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit [ www.heartware.com ].

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: [ ctaylor@heartwareinc.com ]
Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.heartware.com ]


Publication Contributing Sources